-
Mashup Score: 0Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery - 2 year(s) ago
We demonstrate that nebulized scFv76 antibody exhibits therapeutic efficacy in a severe hACE2-transgenic mouse model of COVID-19 pneumonia. Besides previous proof of activity against SARS-CoV-2 Alfa, Beta, Gamma and Delta, here we show that scFv76 can neutralize Omicron BA.1 and BA.2 by recognizing a well-conserved spike epitope modeled by cryo-EM.
Source: Molecular TherapyCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0
Cell-derived exosomes participate in intercellular communications. Through genetic engineering, exosomes could be armed with not only targeting antibodies but also immunomodulatory proteins. These genetically engineered multifunctional immune-modulating exosomes (GEMINI-Exos) are able to induce and sustain robust anti-tumor immunity, providing new strategies for developing therapeutic exosomes.
Source: Molecular TherapyCategories: Latest Headlines, Oncologists2Tweet-
https://t.co/o86sH2EhdH
-
-
Mashup Score: 0Addressing the big business of fake science - 2 year(s) ago
As noted previously in these pages,1 the scientific research community worldwide has been forced to reckon with the increasing problem of scientific fraud and the emergence of so-called “paper mill” industries2 that manufacture fake scientific papers for a fee. The rapid proliferation of such services in the past decade or so, coupled with the pressures upon many young scientists around the globe…
Source: Molecular TherapyCategories: Hem/Oncs, Latest HeadlinesTweet-
Addressing the big business of fake science https://t.co/Qf7L72Jt3A via @herzog_roland et al https://t.co/F0cGu9qaeJ
-
-
Mashup Score: 2Preliminary outcomes reported from three randomized controlled trials of CD19 CAR-T cell therapies in large B cell lymphoma - 2 year(s) ago
The first ever randomized controlled trials (RCTs) testing chimeric antigen receptor (CAR) T cell therapy against a standard of care (SOC) are to be reported at the American Society for Hematology Annual Meeting in December 2021. Based on the published abstracts, the control arms had similar outcomes between the three trials. However, results on the CAR-T cell arms differed, with two of the three…
Source: Molecular TherapyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Preliminary outcomes reported from three randomized controlled trials of CD19 CAR-T cell therapies in LBL https://t.co/RL0yMmI89o #CART #bmtsm #CARTcell #immunotherapy #tcellrx #CARTcells #CellTherapy #Genetherapy @ASTCT #ASH2021 @SaudiLeukemia @riadelfakih @aljurf100 https://t.co/iGiCLoRHW5
-
-
Mashup Score: 1Debulking SARS-COV-2 in saliva using angiotensin converting enzyme 2 in the chewing gum to decrease oral virus transmission and infection - 3 year(s) ago
To advance a novel concept of debulking virus in the oral cavity, the primary site of viral replication, virus trapping proteins CTB-ACE2 were expressed in chloroplasts and clinical grade plant material was developed to meet FDA requirements. Chewing gum (2 grams) containing plant cells expressed CTB-ACE2 up to17.2 mg ACE2/g DW (11.7% leaf protein) have physical characteristics, taste/flavor like…
Source: Molecular TherapyCategories: General Medicine News, Latest HeadlinesTweet-
"Debulking SARS-COV-2 in saliva using angiotensin converting enzyme 2 in the chewing gum to decrease oral virus transmission and infection" - Read more from this @MolTherapy here: https://t.co/KmQOtdCwwW @ResearchatPenn Henry Daniell https://t.co/amxJtK4loa
-
-
Mashup Score: 28Debulking SARS-COV-2 in saliva using angiotensin converting enzyme 2 in the chewing gum to decrease oral virus transmission and infection - 3 year(s) ago
To advance a novel concept of debulking virus in the oral cavity, the primary site of viral replication, virus trapping proteins CTB-ACE2 were expressed in chloroplasts and clinical grade plant material was developed to meet FDA requirements. Chewing gum (2 grams) containing plant cells expressed CTB-ACE2 up to17.2 mg ACE2/g DW (11.7% leaf protein) have physical characteristics, taste/flavor like…
Source: Molecular TherapyCategories: General Medicine News, Latest HeadlinesTweet-
"Debulking SARS-COV-2 in saliva using angiotensin converting enzyme 2 in the chewing gum to decrease oral virus transmission and infection" - Read more from this @MolTherapy here: https://t.co/KmQOtdCwwW @ResearchatPenn Henry Daniell https://t.co/BPuQ1LCCTv
-
-
Mashup Score: 2sEVsRVG selectively delivers antiviral siRNA to fetus brain, inhibits ZIKV infection and mitigates ZIKV-induced microcephaly in mouse model - 3 year(s) ago
R Zhang et al. developed a specific antiviral therapy capable of crossing the placental and blood-brain barriers by designing brain-targeted small extracellular vesicles (sEVs) encapsulating antiviral siRNA (ZIKV specific) to inhibit ZIKV. Their findings suggested that sEVsRVG-siRNA could be a potential therapeutic approach to prevent microcephaly in ZIKV-infected fetal mice during pregnancy.
Source: Molecular TherapyCategories: General Medicine News, Latest HeadlinesTweet-
A gene-silencing therapy suppresses Zika virus transmission from pregnant mice to their fetuses and reduces virus-induced fetal neurological damage. Read more from this @MolTherapy article here: https://t.co/9lt8GqkXMG #NanjingUniversity Zhi Wei Wu, Yongxiang Wang https://t.co/Evgsajwh74
-
-
Mashup Score: 5sEVsRVG selectively delivers antiviral siRNA to fetus brain, inhibits ZIKV infection and mitigates ZIKV-induced microcephaly in mouse model - 3 year(s) ago
R Zhang et al. developed a specific antiviral therapy capable of crossing the placental and blood-brain barriers by designing brain-targeted small extracellular vesicles (sEVs) encapsulating antiviral siRNA (ZIKV specific) to inhibit ZIKV. Their findings suggested that sEVsRVG-siRNA could be a potential therapeutic approach to prevent microcephaly in ZIKV-infected fetal mice during pregnancy.
Source: Molecular TherapyCategories: General Medicine News, Latest HeadlinesTweet-
A gene-silencing therapy suppresses Zika virus transmission from pregnant mice to their fetuses and reduces virus-induced fetal neurological damage. Read more from this @MolTherapy article here: https://t.co/9lt8GqkXMG #NanjingUniversity Zhi Wei Wu, Yongxiang Wang https://t.co/sdJzmWgUlx
-
-
Mashup Score: 1Single dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection - 3 year(s) ago
The coronavirus disease 2019 (COVID-19) pandemic requires the continued development of safe, long-lasting, and efficacious vaccines for preventative responses to major outbreaks around the world, and especially in isolated and developing countries. To combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we characterize a temperature-stable vaccine candidate (TOH-Vac1) that uses a…
Source: Molecular TherapyCategories: Infectious Disease, Latest HeadlinesTweet-
A single dose replicating poxvirus vector-based RBD vaccine 💉 drove robust humoral and T cell immune response against SARS-CoV-2 infection, reports Dr. Carolina Ilkow at the @OttawaHospital Research Insitute and colleagues. https://t.co/F8jQEynQsQ https://t.co/67oTRJe9BW
-
-
Mashup Score: 1Lipid-nanoparticle encapsulated mRNA vaccines induce protective memory CD8 T cells against a lethal viral infection - 3 year(s) ago
It is known that lipid nanoparticle (LNP)-encapsulated mRNA vaccines induce antibodies protective anti-viral antibodies, but whether they can also induce protective memory CD8 T cells is unknown. Sigal and collogues show that mRNA-LNP vaccines induce memory CD8 T cells that protect from mousepox, a highly lethal viral disease.
Source: Molecular TherapyCategories: Infectious Disease, Latest HeadlinesTweet-
Modified mRNA-lipid #nanoparticles can be used to create protective CD8 T cell-based vaccines against #ViralInfections, reports Dr. Luis Sigal's team at @JeffersonUniv. https://t.co/kGr4NIXCYA https://t.co/JfdkfXmzsu
-
#Aerosol 💨 delivery 📨 of an #antibody can counteract #COVID19 lung damage! @Alfasigma_esp researchers demonstrated that a nebulized single-chain antibody exhibits therapeutic efficacy in a transgenic mouse model of COVID-19 #pneumonia. 📑 @MolTherapy | https://t.co/x3UKDcfUrQ https://t.co/W5SuXYSuVd